

UDC 636.2:619:618:579.62:615.331

doi: 10.15389/agrobiology.2018.2.414eng

doi: 10.15389/agrobiology.2018.2.414rus

USE OF PROBIOTICS GIPROLAM AND SIMBITER-2 TO CORRECT THE VAGINA BIOCENOSIS IN DOWN-CALVING COWS

A.G. SHAKHOV, L.Yu. SASHNINA, T.A. YERINA

All-Russian Research Veterinary Institute of Pathology, Pharmacology and Therapy RAAS, Federal Agency of Scientific Organizations, 114-b, ul. Lomonosova, Voronezh, 394087 Russia, e-mail A.G.Shakhov@mail.ru (✉ corresponding author), L.Yu.Sashnina@mail.ru, tatjana_erina@rambler.ru

ORCID:

Shakhov A.G. orcid.org/0000-0002-6177-8858

Yerina T.A. orcid.org/0000-0003-2745-8495

Sashnina L.Yu. orcid.org/0000-0001-6477-6156

The authors declare no conflict of interests

Received January 26, 2016

Abstract

Postpartum endometritis prophylaxis in high producing dairy cows in the intensive animal husbandry is an urgent one because of great economic losses resulted from the productive function disorder, decreased performance and premature culling. Opportunistic pathogenic microflora and disbacteriosis may cause postpartum endometritis along with specific infections. Potentially dangerous pathogenic bacteria from cows with gynecological pathology contaminate the calves at birth, causing gastrointestinal diseases. Various pharmaceuticals and biologicals could be used to prevent postpartum endometritis, including those providing antioxidative effects, immunomodulatory activity, normalization of hormonal and metabolic status in cows' genitals and uterine involution. Antibiotics are in most common use, though their frequent application is accompanied by microecological disorders. Probiotics are considered as a perspective alternative to antibiotics for correcting genital microflora in calving cows. In the paper we report a study of the impact of probiotics Giprolam and Simbiter-2 on microflora of down-calving cows' birth canal in view to prevent postpartum endometritis and intestinal disorders in calves. Thirty-six red-and-white cows with milk yield of 5100-5400 kg for previous lactation were chosen. The cows of the group 1 ($n = 12$) and group 2 ($n = 12$) have received Giprolam and Simbiter-2, respectively, for 5-7 days prior to calving every 24 hours, 100 cm³ intravaginally. The cows of the group 3 ($n = 12$) served as a control (no probiotics). Clinical observations were carried out in mother cows for 14 days after calving, and in the calves during colostrum period. Indigenous and opportunistic microflora was studied in the birth canal before and after calving, in colostrum and in large intestine in the calves. Bacteriologic examination of cervical mucus, reproductive tract discharge, colostrum, excrement, as well as cultural, morphological and biochemical study were performed traditionally. The efficacy of probiotic treatment has been stated. The experiments showed that Giprolam and Simbiter-2 in 71.4 % and 85.8 % cases, respectively, could effectively provide a physiological level of postpartum indigenous microflora, prevent colonization of the reproductive tract by opportunistic and pathogenic microflora and restrict postpartum endometritis. The mother cow treatment with Giprolam and Simbiter-2 could also prevent gastrointestinal diseases in 50.0 % and 41.7 % of the calves, respectively. The high potency of these probiotics is due to lactic acid bacteria capable of genital tract colonization, providing optimal indigenous microflora level and the resistance of the genital tract to harmful microflora.

Keywords: cows, microflora of maternal passages, microflora of colostrum, microflora of intestine in calves, probiotics, postpartum endometritis, prophylaxis

High incidence of acute postpartum endometritis in cows results in significant economic loss due to reproduction malfunction, milk production losses, and anticipated culling of animals [1-5]. Along with agents of infectious diseases [6-8], opportunistic pathogenic microbial flora and disbacteriosis manifested by persistent quantitative and qualitative changes in bacterial community of normal microbial flora plays an important role in the etiology and development of postpartum endometritis [9-11]. At gynecologic pathology in cows, the possible pathogenic bacteria may infect calves at birth causing gastrointestinal diseases [12].

Selenium medicines with antioxidant and immunomodulatory effect [13, 14], medicines from placenta normalizing postpartum hormonal-metabolic and involution processes in genitals [15, 16], preparations intensifying the uterine activity [17-19], and antimicrobial medicines [20-22] are recommended for use to prevent development of postpartum endometritis in cows. One of the main postpartum endometritis preventative measures is use of means eliminating inflammations [23, 24]. Use of antibacterial medicines during 3 days postpartum with preventative purpose does not have significant effect on vaginal microbiocenosis. At the same time, long-term treatment course decreases quantitative and qualitative characteristics of normoflora, increases pH of vaginal secret that prevents recovery of vaginal microbiocenosis postpartum and creates conditions for propagation of opportunistic pathogenic microbial flora [25, 26]. Number of lactobacillus and bifidobacterium is significantly decreased, and opportunistic pathogenic microbial flora increases in the genital tract postpartum causing postpartum purulent-septic diseases due to washing out of microorganisms from vagina by amniotic fluid and blood, traumatization of birth canal, and contamination of vagina by intestinal microflora [27, 28]. Recovery of protective microbial flora at disbiotic disorders without the use of biotherapeutic medicines is challenged as confirmed by disease recurrences [29-33].

Today, use of probiotics as the most essential competitors of pathogenic and opportunistic pathogenic microflora serves as an alternative to antimicrobial medicines [34-37]. However, their use in the first day postpartum does not always prevent occurrence and development of catarrhal endometritis that is due to disbiotic disorders in vaginal microbiotype before birth. In this regard, it is perspective to use probiotic medicines for correction of microbionenosis of birth canals in cows prior to calving.

In present study, we have for the first time shown the need for intravaginal use of probiotics to down-calving cows for prevention of postpartum endometritis that also promote optimization of intestinal microbiocenosis in newborn calves and their addiction to gastrointestinal diseases.

Purpose of this study is to learn corrective effect of Giprolam and Simbiter-2 probiotics on vaginal microbial flora in down-calving cows.

Techniques. Study was carried out in commercial dairy farm Vysokoye (EcoNivaAgro LLC, Liskinsky District, Voronezh Region) in 36 animals of red and pied breed with milk yield in the past lactation of 5100-5400 kg. During interlactation period cows were kept loose housing at deep litter. Groups were formed accounting for the expected calving term. Animals were moved to pre-calving section and, afterwards, to calving section during 10-15 days. Cows were divided into three groups. Within 5-7 days before calving, animals of trial group I ($n = 12$) were treated daily (with 24 hour interval) intravaginally by probiotic medicine Giprolam (Biotechagro LLC, Russia) by Janet's syringe and gynecologic pipette (100 cm³, 5-7 injections). Multiprobiotic Simbiter-2 (Research Industrial Enterprise O.D. Prolisok, Ukraine) was injected intravaginally in cows of trial group II ($n = 12$) according to similar scheme [38]. Medicines were not provided to group III (control, $n = 12$).

Clinical surveillance was performed over cows within 14 days following calving and over calves in colostrum period. State of birth canal microbiocenosis before and after calving, quantitative and qualitative bacterial composition of colostrum and large intestines in calves was assessed by quantity and frequency of occurrence of indigenous and opportunistic pathogenic microbial flora. Bacteriologic tests of cervical mucus, discharges from genital tracts, colostrum, excrements, studying of cultural and morphologic properties of identified microorganisms were carried out by commonly accepted methods [39].

Preventative effectiveness of probiotics was determined by formula:

$$E = 100 \times (B-A)/B,$$

where E stands for effectiveness, %; A and B are disease frequency amongst animals treated and not treated with medicine, % [40].

Obtained results are presented as mean values (M) and standard errors of the mean ($\pm m$).

Results. Giprolam medicine (registration № PVR 1-35.13/02987) is a suspension which contains viable strains of lactobacillus *Lactobacillus fermentum* 44/1 (Russian National Collection of Industrial Microorganisms B-2940) and *Lactococcus lactis* subsp. *lactis* 57₄ (Russian National Collection of Industrial Microorganisms B-3145), nor less than 1×10^8 CFU/cm³, and additional substances (water, milk serum, glucose, and yeast extract). Lactobacillus strains are able to succeed in birth canals of cows and have antagonistic effect on opportunistic pathogenic microbial flora penetrating to womb. Multiprobiotic Simbiter-2 — is a multicomponent medicine for normalization of vaginal microflora in female organism. Medicine is based on the key protective microorganisms of urogenital tract, i.e. bacteria *Lactobacillus acidophilus*, *L. casei*, *L. plantarum*, *L. gasseri*, *L. brevis*, *Bifidobacterium bifidum*, *B. longum*, *B. breve*, *B. infantis*, *B. adolescentis*, *Propionibacterium freudenreichii* ssp. *shermanii*, *P. acidipropionici*. They actively ferment glycogen to organic acids, synthesize hydrogen peroxide, bacteriocine and lysozyme having high adhesive ability regarding epitheliocytes, produce vitamins and polysaccharides [38].

1. Microbial flora (lg CFU/cm³) of birth canals in red and pied cows at treatment by Giprolam and Simbiter-2 probiotics ($M \pm m$)

Bacteria	Group I	Group II	Group III
<i>Lactobacillus</i> spp.	7.53±0.59*	7.64±0.83*	6.55±0.71*
	7.64±0.61*	7.58±0.10*	5.64±0.94*
<i>Bifidobacterium</i> spp.	7.64±0.72*	7.78±0.69*	6.50±0.46*
	7.75±0.86*	7.54±0.73*	5.47±0.68*
<i>Corynebacterium</i> spp.	2.25±0.02*	2.49±0.17*	2.32±0.19*
	2.20±0.01*	2.66±0.23*	3.51±0.41*
<i>Staphylococcus saprophyticus</i>	5.52±0.49*	4.61±0.16*	5.86±0.12*
	5.76±0.17*	4.55±0.21*	5.61±0.81*
<i>Staphylococcus epidermidis</i>	3.64±0.02*	4.62±0.61*	5.37±0.25*
	4.54±0.74*	5.59±0.32*	4.32±0.17*
<i>Staphylococcus aureus</i>	not isolated	not isolated	not isolated
	not isolated	not isolated	4.32±0.03 (25.0)
<i>Streptococcus</i> group C	4.50±0.16 (50.0)	4.57±0.69 (25.0)	5.70±0.45 (75.0)
	4.43±0.58 (50.0)	4.51±0.65 (33.3)	6.64±0.81 (75.0)
<i>Enterococcus faecalis</i>	not isolated	3.95±0.01 (16.7)	3.67±0.22 (25.0)
	2.63±0.01 (25.0)	3.49±0.01 (25.0)	4.35±0.85 (75.0)
<i>Streptococcus</i> spp. hemolytic	not isolated	2.56±0.86 (8.3)	5.68±0.38 (25.0)
	3.91±0.01 (25.0)	3.64±0.73 (8.3)	5.39±0.52 (75.0)
<i>Enterobacter</i> spp.	not isolated	2.77±0.85 (8.3)	not isolated
	not isolated	not isolated	4.49±0.02 (25.0)
<i>Escherichia coli</i>	2.51±0.89 (25.0)	3.46±0.25 (16.7)	4.52±0.74 (25.0)
	not isolated	not isolated	5.70±0.65 (50.0)

Note. See description of groups in section "Methodology". Figures in parenthesis show frequency of isolation, %; microorganisms marked by star were identified in 100 % of animals. Values prior calving and after calving are above and under bar, respectively.

Microflora of birth canals before administration of medicines (Table 1) and in control group within 5-7 days before calving did not significantly differ. *Lactobacillus*, bifidobacteria, *Corynebacterium* spp., *Staphylococcus saprophyticus* and *S. epidermidis* were found in all specimens, while *Streptococcus* group C and *Escherichia coli* were rare. Besides, hemolytic streptococci *Enterococcus faecalis* were found prior to administration of Simbiter-2 in group II and in control animals, and *Enterobacter* spp. — prior to treatment with the probiotic (see Table 1).

During the period before calving, due to Giprolam, positive dynamics in lactobacillus (growth by 1.5 %), bifidobacteria (by 1.4 %), *Staphylococcus saprophyti-*

cus (by 4.2 %), and epidermal staphylococcus (by 19.9 %) counts occurs in birth canal, with notable trend towards reduction of the number of streptococcus group C (by 1.6 %). In 25.0 % cases, *Enterococcus faecalis* and hemolytic streptococci but no *Escherichia* were isolated (see Table 1). Prior to administration of Simbiter-2, number of lactobacillus and bifidobacteria was optimal, number of epidermal staphylococci grew by 17.4 %, hemolytic streptococci grew by 29.7 %, and number of *Enterococcus faecalis* decreased by 11.7 %. *Escherichia* and *Enterobacter* spp. were not found (see Table 1).

After calving, abundance of lactobacillus (by 13.9%), bifidobacterium (by 15.9%) was reduced in the control group with increase of the number of opportunistic pathogenic microflora: streptococci group C — by 14.2 %, *Enterococcus faecalis* — by 15.7 %, *Escherichia* — by 20.7 %. Frequency of isolation of *Enterococcus faecalis*, hemolytic streptococci and *Escherichia* increased by 50.0; 50.0 and 25.0 %, respectively, besides, at frequency of 25.0 %, staphylococci aureus and *Enterobacter* spp. were isolated (see Table 1). In group I, number of lactobacilli and bifidobacteria was 26.2 and 29.4 % higher than in control, while abundance and frequency of streptococci group C was 33.3 and 25.0 % lower than in control, *Enterococcus faecalis* — by 39.6 and 50.0 %, hemolytic streptococci — by 27.5 and 50.0 % lower. *Staphylococci aureus*, *Escherichia* and *Enterobacter* spp. were not found. Number of lactobacilli in group II as compared to control was 25.6 % higher, of bifidobacteria —27.5 % higher, count of streptococci group C was 32.1 % lower, of *Enterococcus faecalis* — 32.5 % lower, hemolytic streptococci — 19.8 % lower. *Staphylococci aureus*, *Escherichia* and *Enterobacter* spp. were not found. In animals treated by Simbiter-2 frequency of hemolytic streptococci and streptococci group C was 16.7 % lower than in animals treated with Giprolam.

2. Preventative effectiveness of use of Giprolam and Simbiter-2 probiotics in red and pied cows

Indicator	Group I	Group II	Group III
Number of animals	12	12	12
Delivery, min ($M \pm m$)	60 ± 10	30 ± 10	120 ± 30
Postpartum endometritis, number (%)	2 (16.7)	1 (8.3)	7 (58.3)
Preventative effectiveness, %	71.4	85.8	

Note. See description of groups in section "Methodology".

Calving in cows treated with probiotics was without obstetric aid, while frequency of purulent-catarrhal endometritis did not exceed 16.7 % (Table 2). In control in 50.0 % cases, cows were rendered with obstetric aid,

fetal removal was 2 and 4 times longer than in groups I and II, one cow and its calf died, and acute purulent-catarrhal endometritis was in over half of animals (see Table 2).

Intravaginal injection of Giprolam and Simbiter-2 in down-calving cows promotes postpartum indigenous microflora at physiological level, prevents colonization of birth canals by opportunistic pathogenic microflora and occurrence of postpartum endometritis in 71.4 and 85.8 % cases.

Correction of birth canal biocenosis in cows was accompanied by optimization of quantitative and qualitative composition of colostrum microflora. In day 1 postpartum, in colostrum of animals treated with Giprolam the number of lactobacilli and bifidobacteria was 9.8 and 29.2 times higher than in control, *Staphylococcus epidermidis* was 6.6 times less; *Staphylococci aureus*, streptococci group D and *Escherichia* were not found. Colostrum of cows from group II contained 6.7 and 17.5 times more lactobacilli and bifidobacteria, 1.5 times less *Staphylococcus epidermidis*. *Staphylococcus aureus* was 2.3 times less frequent at 11 times lower count; streptococci group D and *Escherichia* found in the control with frequencies of 25.0 and 8.3 % were not isolated. Comparison of Giprolam

and Simbiter-2 effects shows that Giprolam increases number of lactobacilli and bifidobacteria 1.5- and 1.7-fold, *Staphylococcus epidermidis* was 4.3 times less, and *Staphylococcus aureus* was not found.

Intravaginal administration of probiotics had positive effect on formation of gastrointestinal normoflora in calves, formation of which starts from fetal movement through the mother's birth canals and directly depends of the sanitary quality and timely production of colostrum (milk), being the lactobacillus and bifidobacterium source. In the day 1 of life, quantity of lactobacillus in the large intestines of calves from cows treated with Giprolam, as compared to control, was 237.4 times higher, bifidobacteria — 38.9 times higher, and lactose positive *Escherichia* — 2.2 times higher than in control, ratio of the latter and lactose negative *E. coli* increased 17.7 times; quantity of *Enterobacter* and *Citrobacter* genera was 3.5 and 10.7 times less; staphylococci and protei were not found. On day 7, quantity of lactobacilli and bifidobacteria was 165.5 and 131.3 times higher, saprophyte staphylococci was 8.3 times higher; opportunistic pathogenic microorganisms *Enterococcus faecalis* was 21.7 times less, *Enterococcus faecium* — 25.3 times less, lactose negative *Escherichia* — 8.7 times less, *Citrobacter* and *Enterobacter* genera — 10.9 and 18.5 times less. On day 1, quantity of lactobacilli was 19.7 times higher than in the control, bifidobacteria — 15.6 times higher, lactose positive *Escherichia* — 16.3 times higher; opportunistic pathogenic *Citrobacter* and *Enterobacter* bacteria were 29.7 and 7.4 times less; *Staphylococcus aureus* and protei were not found on day 1 in the large intestines of calves from cows treated with Simbiter-2. Optimization of normaflora in calves during colostrum period due to microecologic effects of Giprolam and Simbiter-2 prevents gastrointestinal diseases in calves in 50.0 and 41.7 % cases, respectively.

Therefore, correction of vaginal biocenosis in down-calving cows by Giprolam and Simbiter-2 to a significant degree prevents development of acute postpartum endometritis. High effectiveness of use of such probiotics is due to ability of lactobacilli to colonize birth canals of mother-cows and maintain the optimal composition of indigenous microflora to prevent infection by pathogenic microorganisms and excessive colonization of birth canals by opportunistic pathogenic bacteria. Such treatment also optimizes quantitative and qualitative microflora composition of colostrum and intestines of calves that prevents their gastrointestinal diseases.

REFERENCES

1. Nezhdanov A.G., Shakhov A.G. *Veterinarnaya patologiya*, 2005, 3: 61-64 (in Russ.).
2. Le Blanc S.J., Duffield T.F., Leslie K.E., Bateman K.G., Keefe G.P., Walton J.S., Johnson W.H. Defining and diagnosing postpartum clinical endometritis and its impact on reproductive performance in dairy cows. *American Dairy Science Association*, 2002, 85: 2223-2236 (doi: 10.3168/jds.S0022-0302(02)74302-6).
3. Gilbert R.O., Shin S.T., Guard C.L., Erb H.N., Marcel F. Prevalence of endometritis and its effects on reproductive performance of dairy cows. *Theriogenology*, 2005, 64(9): 1879-1888 (doi: 10.1016/j.theriogenology.2005.04.022).
4. Gautam G., Nakao T., Yusuf M., Koike K. Prevalence of endometritis during the postpartum period and its impact on subsequent reproductive performance in two Japanese dairy herds. *Anim. Reprod. Sci.*, 2009, 116(3-4): 175-187 (doi: 10.1016/j.anireprosci.2009.02.001).
5. Dubuc J., Duffield T.F., Leslie K.E., Walton J.S., Leblanc S.J. Effects of postpartum uterine diseases on milk production and culling in dairy cows. *J. Dairy Sci.*, 2011, 94(3): 1339-1346 (doi: 10.3168/jds.2010-3758).
6. Donofrio G., Herath S., Sartori C., Cavarani S., Flammini F., Sheldon I.M. Bovine herpesvirus 4 is tropic for bovine endometrial cells and modulates endocrine function. *Reproduction*, 2007, 134(1): 183-197 (doi: 10.1530/REP-07-0065).
7. Donofrio G., Ravanetti L., Cavarani S., Herath S., Capocefalo A., Sheldon I.M. Bacterial infection of endometrial stromal cells influences bovine herpesvirus 4 immediate early gene activa-

- tion: a new insight into bacterial and viral interaction for uterine disease. *Reproduction*, 2008, 136(3): 361-366 (doi: 10.1530/REP-08-0171).
8. Fábrián K., Makrai L., Sachse K., Szeredi L., Egyed L. An investigation of the aetiological role of bovine herpesvirus 4 in bovine endometritis. *Vet. J.*, 2008, 177(2): 289-292 (doi: 10.1016/j.tvjl.2007.04.010).
 9. Liu M.C., Wu C.M., Liu Y.C., Zhao J.C., Yang Y.L., Shen J.Z. Identification, susceptibility, and detection of integron cassettes of *Arcanobacterium pyogenes* in bovine endometritis. *J. Dairy Sci.*, 2009, 92(8): 3659-3666 (doi: 10.3168/jds.2008-1756).
 10. Petit T., Spersger J., Rosengarten R., Aurich J. Prevalence of potentially pathogenic bacteria as genital pathogens in dairy cattle. *Reprod. Domest. Anim.*, 2009, 44(1): 88-91 (doi: 10.1111/j.1439-0531.2007.01002.x).
 11. Bicalho R.C., Machado V.S., Bicalho M.L., Gilbert R.O., Teixeira A.G., Caixeta L.S., Pereira R.V. Molecular and epidemiological characterization of bovine intrauterine *Escherichia coli*. *J. Dairy Sci.*, 2010, 93(12): 5818-5830 (doi: 10.3168/jds.2010-3550).
 12. Samokhin V.T., Shakhov A.G., Shegidevich E.I., Fedorov Yu.N., Yurov K.P., Zhidkov S.A., Voronin E.S., Arkhipov A.V., Burlakov A.V., Subbotin V.V., Ivkin N.S., Donchenko A.S., Shkil' N.A., Volkov G.K., Sidorov M.A., Ovsyannikova T.O., Sisyagin P.N., Kavruk L.S., Nikitin V.F., Antipov V.A., Terekhov V.I., Shipitsyn A.G., Petrov Yu.F., Degtyarev V.P. *Nauchno obosnovannaya sistema polucheniya zdorovogo molodnyaka i profilaktika zheludochno-kishechnykh boleznei novorozhdennykh telyat* [A grounded system for producing healthy young animals and preventing gastrointestinal diseases of newborn calves]. Moscow, 2002 (in Russ.).
 13. Cerri R.L., Rutigliano H.M., Lima F.S., Araújo D.B., Santos J.E. Effect of source of supplemental selenium on uterine health and embryo quality in high-producing dairy cows. *Theriogenology*, 2009, 71(7): 1127-1137 (doi: 10.1016/j.theriogenology.2008.12.005).
 14. Brozos C.N., Kioussis E., Georgiadis M.P., Piperelis S., Boscos C. The effect of chloride ammonium, vitamin E and Se supplementation throughout the dry period on the prevention of retained fetal membranes, reproductive performance and milk yield of dairy cows. *Livestock Science*, 2009, 124(1-3): 210-215 (doi: 10.1016/j.livsci.2009.01.018).
 15. Lobodin K.A. *Veterinariya*, 2006, 7: 38-42. Available <https://elibrary.ru/item.asp?id=9242726>. No date (in Russ.).
 16. Kornienko V.S. *Lekarstvennyi preparat Ban. A.S. 2140275 (RF) MKIZ A61K35/12, A61K35/50. Filial № 5 GNTS — Institut biofiziki FU «Medbioekstrem» pri MZ Rossii № 98110825/13. Zayavl. 04.06.98. Opubl. 27.10.99* [Medication Ban. A.C. 2140275 (RF) MKI3 A61K35/12, A61K35/50. Appl. 04.06.98. Publ. 27.10.99] (in Russ.).
 17. Arlt S., Padberg W., Drillich M., Heuwieser W. Efficacy of homeopathic remedies as prophylaxis of bovine endometritis. *J. Dairy Sci.*, 2009, 92(10): 4945-4953 (doi: 10.3168/jds.2009-2142).
 18. Barrett A.J., Murray R.D., Christley R.M., Dobson H., Smith R.F. Effects of the administration of oxytocin or carbetocin to dairy cows at parturition on their subsequent fertility. *Vet. Rec.*, 2009, 165(21): 623-626 (doi: 10.1136/vr.165.21.623).
 19. Zidane K., Niar A., Tainturier D. Comparative effect on clinical use of PGF2 and REPRO-CINE in the treatment of retained placenta in dairy cows at Tiaret region (Algeria). *Asian Journal of Animals and Veterinary Advances*, 2011, 6(6): 593-598 (doi: 10.3923/ajava.2011.593.598).
 20. Runciman D.J., Anderson G.A., Malmo J., Davis G.M. Effect of intrauterine treatment with cephalosporin on the reproductive performance of seasonally calving dairy cows at risk of endometritis following periparturient disease. *Aust. Vet. J.*, 2008, 86(7): 250-258 (doi: 10.1111/j.1751-0813.2008.00302.x).
 21. Galvão K.N., Greco L.F., Vilela J.M., SáFilho M.F., Santos J.E. Effect of intrauterine infusion of ceftiofur on uterine health and fertility in dairy cows. *J. Dairy Sci.*, 2009, 92(4): 1532-1542 (doi: 10.3168/jds.2008-1615).
 22. Kaufmann T.B., Westermann S., Drillich M., Plöntzke J., Heuwieser W. Systemic antibiotic treatment of clinical endometritis in dairy cows with ceftiofur or two doses of cloprostenol in a 14-d interval. *Anim. Reprod. Sci.*, 2010, 121: 55-62 (doi: 10.1016/j.anireprosci.2010.04.190).
 23. Machado V.S., Bicalho M.L.S., Pereira R.V., Caixeta L.S., Bittar J.H.J., Oikonomou G., Gilbert R.O., Bicalho R.C. The effect of intrauterine administration of mannose or bacteriophage on uterine health and fertility of dairy cows with special focus on *Escherichia coli* and *Arcanobacterium pyogenes*. *J. Dairy Sci.*, 2012, 95: 3100-3109 (10.3168/jds.2011-5063)
 24. Changjun X., Minglei H., Daqing G., Jinghua G., Guizhen X., Jianwei L., Hongbo N. Therapeutic efficacy experiments of Xuyanning in treating endometritis of dairy cows. *Journal of Heilongjiang Bayi Agricultural University*, 2012, 2. Available https://en.cnki.com.cn/Article_en/CJFDTOTAL-HLJK201202016.htm. No date.
 25. Kira E.F. *Bakterial'nyi vaginoz* [Bacterial vaginosis]. St. Petersburg, 2001 (in Russ.).
 26. Kolesaeva Zh.Yu., Martikainen Z.M., Savicheva A.M., Tarasova M.A. *Zhurnal akusherstva i zhenskikh boleznei*, 2009, 3: 25-31 (in Russ.).
 27. Dobrokhotova Yu.Z., Zatikyan N.G. *Akusherstvo, ginekologiya, reproduktivsiya*, 2008, 1: 7-9. Available <http://www.gyn.su/article.php?what=21>. No date (in Russ.).
 28. Garoussi M.T., Khosravy A.R., Havareshi P. Mycoflora of cervicovaginal fluids in dairy

- cows with or without reproductive disorders. *Mycopathologia*, 2007, 164(2): 97-100 (doi: 10.1007/s11046-007-9031-x).
29. Ankirskaya A.S. *Akusherstvo i ginekologiya*, 1995, 6: 13-16 (in Russ.).
 30. Lincke A., Drillich M., Heuwieser W. Die subklinische Endometritis des Rindes und ihr Einfluss auf die Fruchtbarkeit eine Übersicht neuerer Untersuchungen. *Berl. Münch. Tierärztl. Wschr.*, 2007, 120(5-6): 245-250 (doi: 10.2376/0005-9366-120-245).
 31. LeBlans S.J. Postpartum uterine disease and dairy herd reproductive performance: a review. *Vet. J.*, 2008, 176(1): 102-114 (doi: 10.1016/j.tvjl.2007.12.019).
 32. Dolezel R., Vecera M., Palenik T., Cech S., Vyskocil M. Systematic clinical examination of early postpartum cows and treatment of puerperal metritis did not have any beneficial effect on subsequent reproductive performance. *Veterinari Medicina*, 2008, 53(2): 59-69. Available <http://www.vri.cz/docs/vetmed/53-2-59.pdf>. No date (in Russ.).
 33. Santos T.M., Caixeta L.S., Machado V.S., Rauf A.K., Gilbert R.O., Bicalho R.C. Antimicrobial resistance and presence of virulence factor genes in *Arcanobacterium pyogenes* isolated from the uterus of postpartum dairy cows. *Vet. Microbiol.*, 2010, 145(1-2): 84-89 (doi: 10.1016/j.vetmic.2010.03.001).
 34. Turchenko A.N., Koba I.S., Novikova E.N., Reshetka M.B., Petenko A.I., Gorpichenko E.A. *Veterinariya Kubani*, 2012, 3: 11-13. Available <https://elibrary.ru/item.asp?id=17785427>. No date (in Russ.).
 35. Otero M.C., Morelli L., Nader-Macias M.E. Probiotic properties of vaginal lactic acid bacteria to prevent metritis in cattle. *Letters in Applied Microbiology*, 2006, 43: 91-97 (doi: 10.1111/j.1472-765X.2006.01914.x).
 36. Fátima M., Nader-Macías E., Claudia O.M., Carolina E.M., Natalia M.C. Advances in the design of probiotic products for the prevention of major diseases in dairy cattle. *Journal of Industrial Microbiology & Biotechnology*, 2008, 35(11): 1387-1395 (doi: 10.1007/s10295-008-0438-2).
 37. Ametaj B.N., Iqbal S., Selami F., Odhiambo J.F., Wang Y., Gänzle M.G., Dunn S.M., Zebeli Q. Intravaginal administration of lactic acid bacteria modulated the incidence of purulent vaginal discharges, plasma haptoglobin concentrations, and milk production in dairy cows. *Research in Veterinary Science*, 2014, 96(2): 365-370 (doi: 10.1016/j.rvsc.2014.02.007).
 38. Yankovskii D.S. *Mikrobnaya ekologiya cheloveka: sovremennye vozmozhnosti ee podderzhaniya i vosstanovleniya* [Microbial human ecology maintenance and restoration: modern approaches]. Kiev, 2005. Available <https://lad.mosuzi.ru/antropologiya/d7f4f702361368547686f389025d7bda>. No date (in Russ.).
 39. Sidorov M.A., Skorodumov D.I., Fedotov V.B. *Opređitel' zoopatogennykh mikroorganizmov* [Identification keys of zoopathogenic microorganisms]. Moscow, 1995 (in Russ.).
 40. Belyakov V.D. *Immunoprofilaktika v immunologii* [Immunoprophylaxis in immunology]. Moscow, 1961 (in Russ.).